Thursday, January 10, 2008

Reversal Of Alzheimer's Symptoms Within Minutes In Human Study

This could be an important research finding for adults with DS!

Reversal Of Alzheimer's Symptoms Within Minutes In Human Study ScienceDaily (Jan. 9, 2008) — An extraordinary new scientific study, which for the first time documents marked improvement in Alzheimer's disease within minutes of administration of a therapeutic molecule, has just been published in the Journal of Neuroinflammation. This new study highlights the importance of certain soluble proteins, called cytokines, in Alzheimer's disease. The study focuses on one of these cytokines, tumor necrosis factor-alpha(

TNF), a critical
component of the brain's immune system. Normally, TNF finely
regulates the transmission of neural impulses in the brain. The
authors hypothesized that elevated levels of TNF in Alzheimer's
disease interfere with this regulation. To reduce elevated TNF, the
authors gave patients an injection of an anti-TNF therapeutic called
etanercept. Excess TNF-alpha has been documented in the cerebrospinal
fluid of patients with Alzheimer's.

The new study documents a dramatic and unprecedented therapeutic
effect in an Alzheimer's patient: improvement within minutes
following delivery of perispinal etanercept, which is etanercept
given by injection in the spine. Etanercept (trade name Enbrel) binds
and inactivates excess TNF. Etanercept is FDA approved to treat a
number of immune-mediated disorders and is used off label in the
study.

The use of anti-TNF therapeutics as a new treatment choice for many
diseases, such as rheumatoid arthritis and potentially even
Alzheimer's, was recently chosen as one of the top 10 health stories
of 2007 by the Harvard Health Letter.

Similarly, the Neurotechnology Industry Organization has recently
selected new treatment targets revealed by neuroimmunology (such as
excess TNF) as one of the top 10 Neuroscience Trends of 2007. And the
Dana Alliance for Brain Initiatives has chosen the pilot study using
perispinal etanercept for Alzheimer's for inclusion and discussion in
their 2007 Progress Report on Brain Research.

The lead author of the study, Edward Tobinick M.D., is an assistant
clinical professor of medicine at the University of California, Los
Angeles and director of the Institute for Neurological Research, a
private medical group in Los Angeles. Hyman Gross, M.D., clinical
professor of neurology at the University of Southern California, was
co-author.

The study is accompanied by an extensive commentary by Sue Griffin,
Ph.D., director of research at the Donald W. Reynolds Institute on
Aging at the University of Arkansas for Medical Sciences (UAMS) in
Little Rock and at the Geriatric Research and Clinical Center at the
VA Hospital in Little Rock, who along with Robert Mrak, M.D.,
chairman of pathology at University of Toledo Medical School, are
editors-in-chief of the Journal of Neuroinflammation.

Griffin and Mrak are pioneers in the field of neuroinflammation.
Griffin published a landmark study in 1989 describing the association
of cytokine overexpression in the brain and Alzheimer's disease. Her
research helped pave the way for the findings of the present study.
Griffin has recently been selected for membership in the Dana
Alliance for Brain Initiatives, a nonprofit organization of more than
200 leading neuroscientists, including ten Nobel laureates.

"It is unprecedented that we can see cognitive and behavioral
improvement in a patient with established dementia within minutes of
therapeutic intervention,
" said Griffin. "It is imperative that the
medical and scientific communities immediately undertake to further
investigate and characterize the physiologic mechanisms involved.
This gives all of us in Alzheimer's research a tremendous new clue
about new avenues of research, which is so exciting and so needed in
the field of Alzheimer's. Even though this report predominantly
discusses a single patient, it is of significant scientific interest
because of the potential insight it may give into the processes
involved in the brain dysfunction of Alzheimer's.
"

While the article discusses one patient, many other patients with
mild to severe Alzheimer's received the treatment and all have shown
sustained and marked improvement.

The new study, entitled "Rapid cognitive improvement in Alzheimer's
disease following perispinal etanercept administration,
" and the
accompanying commentary, entitled "Perispinal etanercept: Potential
as an Alzheimer's therapeutic,
" are available on the Web site of the
Journal of Neuroinflammation
(http://www.jneuroinflammation.com/content/5/1/2/abstract).

Author Hyman Gross, M.D., has no competing interests. Author Edward
Tobinick, M.D. owns stock in Amgen, the manufacturer of etanercept,
and has multiple issued and pending patents assigned to TACT IP LLC
that describe the parenteral and perispinal use of etanercept for the
treatment of Alzheimer's disease and other neurological disorders,
including, but not limited to, U.S. patents 6015557, 6177077,
6419934, 6419944, 6537549, 6982089, 7214658 and Australian patent
758523.

Adapted from materials provided by University of Arkansas for Medical
Sciences.

Monday, January 7, 2008

Down Syndrome Center at Rady Children's Hospital - San Diego, CA

Posting this with permission from the list it was posted on.

-----------
Hi everyone!

I've been too busy helping with this to post lately, but we're trying
to get the word out to everyone that the DS Center at Rady Children's
Hospital-San Diego will open on Janaury 15th! Please forward this to
anyone you know in the surrounding areas/states too.

For more info and the call in number for appointments, go to
www.dsaction.com

Thanks!
Lisa
---------------

Friday, January 4, 2008

The Changes We've Seen

The changes we've seen with my brother and Ginkgo Biloba is his attention span and being able to focus better.

His attention span is great and he is able to focus really well. His delayed response time is very minimal.

We've noticed some changes in him lately, which I don't know if they are directly to the GB or not, but nonetheless it is interesting.

He can be given two things to do and he's able to do both of them without doing only the one thing. Like after we've fed him yogurt. There's the yogurt container that has to be thrown in the trash can and there's the spoon that has to be put in the sink. We give him both of them and tell him what to do with each one and he goes and puts the one in the trash and the other in the sink. A few months ago, he would have only been able to do one or the other, not remember to keep them both separate. Now, whether this is due to the GB, or just that he is getting older (will be 3 y/o in February), I don't know.

The other day when I was doing the stacking rings with him. Normally he picks up the smallest two rings first for whatever reason, but that is what he always does. Sometimes I'll stack them up the wrong way so that as he takes the first ones off the top of the stack, he puts them on the stacking toy in the right order. But, the other day I decided to leave them all laying there and just ask him to put the right one on to see if he could do it in the right order. He went to pick up the two smallest two and I said, "no, those don't go on first, can you pick up the red one?" He put down the smallest two, looked around at the pieces and picked up the red one and put it on. He did it with all the pieces . . . orange, green, yellow, dark blue, etc. He ended up doing it two times in a row! I was so excited. Again, I don't know if this is related to the GB, or another supplement, or if he is just growing.

Nonetheless, changes similar to these are the things that we've noticed with him and the GB.

Zinc status in Down syndrome

As has been found in other studies, zinc is low in individuals with Down syndrome.

Zinc nutritional status in adolescents with Down syndrome.

Universidade Federal do Piauí, Teresina, Piauí, Brazil.

Studies have evidenced that zinc metabolism is altered in presence of Down syndrome, and zinc seems to have a relationship with the metabolic alterations usually present in this syndrome. In this work, the Zn-related nutritional status of adolescents with Down syndrome was evaluated by means of biochemical parameters and diet. A case-control study was performed in a group of adolescents with Down syndrome (n = 30) and a control group (n = 32), of both sexes, aged 10 to 19 years. Diet evaluation was accomplished by using a 3-day dietary record, and the analysis was performed by the NutWin program, version 1.5. Antropometric measurements were performed for evaluation of body composition. The Zn-related nutritional status of the groups was evaluated by means of zinc concentration determinations in plasma and erythrocytes, and 24-h urinary zinc excretion, by using the method of atomic absorption spectroscopy. The diet of both groups presented adequate concentrations of lipids, proteins, carbohydrates, and zinc. The mean values found for zinc concentration in erythrocytes were 49.2 +/- 8.5 microg Zn/g Hb for the Down syndrome group and 35.9 +/- 6.1 microg Zn/g Hb for the control group (p = 0.001). The average values found for zinc concentration in plasma were 67.6 +/- 25.6 microg/dL for the Down syndrome group and 68.9 +/- 22.3 microg/dL for the control group. The mean values found for zinc concentration in urine were 244.3 +/- 194.9 microg Zn/24 h for the Down syndrome group and 200.3 +/- 236.4 microg Zn/24 h for the control group. Assessment of body composition revealed overweight (26.7%) and obesity (6.6%) in the Down syndrome group. In this study, patients with Down syndrome presented altered zinc levels for some cellular compartments, and the average zinc concentrations were low in plasma and urine and elevated in erythrocytes.

Speaking of Neurogenesis . . .


The Changing Minds protocol and all was being discussed on some of the DS lists I am. I know at least part of Dr. Cody's protocol is based on improving Neurogenesis in DS. As I was searching PubMed I happened to run across this abstract that was just published in December. It shows that there are reduced numbers of neurons in the brains of babies with DS (in the hippocampal region) and this is partly caused by an impairment of neurogenesis. Just thought it was interesting and maybe others may find it interesting.

Neurogenesis Impairment and Increased Cell Death Reduce Total Neuron Number in the Hippocampal Region of Fetuses with Down Syndrome.

Dipartimento di Fisiologia Umana e Generale, Università di Bologna, Bologna, Italy.

We previously obtained evidence for reduced cell proliferation in the dentate gyrus (DG) of fetuses with Down syndrome (DS), suggesting that the hippocampal hypoplasia seen in adulthood may be caused by defective early neuron production. The goal of this study was to establish whether DS fetuses (17-21 weeks of gestation) exhibit reduction in total cell number in the DG, hippocampus and parahippocampal gyrus (PHG). Volumes of the cellular layers and cell number were estimated with Cavalieri's principle and the optical fractionator method, respectively. We found that in DS fetuses all investigated structures had a reduced volume and cell number. Analysis of cell phenotype showed that DS fetuses had a higher percentage of cells with astrocytic phenotype but a smaller percentage of cells with neuronal phenotype. Immunohistochemistry for Ki-67, a marker of cycling cells, showed that DS fetuses had less proliferating cells in the germinal zones of the hippocampus and PHG. We additionally found that in the hippocampal region of DS fetuses there was a higher incidence of apoptotic cell death. Results show reduced neuron number in the DS hippocampal region and suggest that this defect is caused by disruption of neurogenesis and apoptosis, two fundamental processes underlying brain building.


The Brain of a Baby With DS


I thought this was interesting. It was just published in November. The link to the full text is below. It kind of goes along the lines of what was discussed several months ago (maybe a year or more by now) on the ES list of the brain of a baby with DS being normal or abnormal from the get-go.


Fetal Down Syndrome Brains Exhibit Aberrant Levels of Neurotransmitters Critical for Normal Brain Development


Nigel Whittle, MAppScia, Simone B. Sartori, PhDa, Mara Dierssen, MD, PhDb, Gert Lubec, MDc and Nicolas Singewald, PhDa BACKGROUND. In the immature developing fetal brain, amino acids (such as -aminobutyric acid, and taurine) and monoamines (serotonin, noradrenaline, and dopamine) act as developmental signals or regulators. In subjects with Down syndrome, dysfunctional brain development is evident from birth as reduction in brain weight, as well as volume reductions in specific brain regions, and an altered number of neurons, dendrites, and dendritic branching is observed. However, mechanisms that underlie the observed dysfunctional brain development in Down syndrome are not clear. OBJECTIVES. Because diverse amino acids and monoamines are critical for normal brain development, we wanted to determine whether dysfunctional brain development observed in subjects with Down syndrome is associated with altered brain amino acid and/or monoamine levels. DESIGN/METHODS. We quantified tissue concentrations of diverse amino acids, including -aminobutyric acid and taurine, and the monoamines serotonin, noradrenaline, and dopamine in the frontal cortex of fetal Down syndrome tissue at a gestational age of 20 weeks versus age-matched control aborted fetuses. RESULTS. Fetal Down syndrome brains showed reductions in the levels of serotonin, -aminobutyric acid, taurine, and dopamine in the frontal cortex. No alteration in the levels of arginine, aspartate, glutamine, glutamate, glycine, histidine, serine, or noradrenaline was observed. CONCLUSIONS. Serotonin, -aminobutyric acid, taurine, and dopamine are critical for the acquisition of brain morphologic features, neuronal and glia proliferation, and synapse formation. The detected reductions in the levels of these neurotransmitters may indicate potential mechanisms for the observed dysfunctional neuronal development in the Down syndrome fetal brain. http://pediatrics.aappublications.org/cgi/content/full/120/6/e1465

Friday, December 28, 2007

New ACOG guidelines: Invasive prenatal testing should be offered to all pregnant women


This makes me want to get our book finished all the more and sooner! Doctors and many others need to be educated about Down syndrome.

The ACOG put new guidelines out in January/February of 2006 that recommended all pregnant women be screened for Down syndrome. 90% of babies who are prenatally diagnosed with Down syndrome are aborted. That statistic is disgusting! It seems as if the ACOG is trying to "rid the world" of people with Down syndrome. It's terrible that these babies are aborted because of a chromosomal abnormality, which they had nothing to do with. God is the one who made them with that extra chromosome. Our society has warped views that they have to have "the perfect child." But, what's also terrible is that the amniocentesis and the CVS screenings are not even accurate. They have a lot of false negatives and false positives.


New ACOG guidelines: Invasive prenatal testing should be offered to all pregnant women.

From Obstetrics & Gynecology, Volume 110, No. 6, December 2007, page 1459 (ACOG membership or $20 payment required for articles.)

Heralding a change in standard obstetric practice, the American College of Obstetricians and Gynecologists has recommended that pregnant women of all ages – not just women aged 35 and over — should be offered invasive prenatal diagnostic testing such as amniocentesis and chorionic villus sampling to detect possible genetic abnormalities in their fetuses.

The recommendation, published in a practice bulletin in the December issue of the organization’s journal Obstetrics & Gynecology, dramatically expands women’s access to prenatal diagnosis, effectively making all prenatal tests and screens available to all of the 6 million American women who get pregnant each year. It will establish a new standard of care, and change expectations for insurance coverage and legal liability involving pregnancy.

Until now, obstetricians have usually offered invasive testing just to women at or above age 35 at delivery. The age threshold was chosen because at that age the risk of miscarriage as a result of the testing was roughly equal to the risk of having a child with Down syndrome, the most common genetic abnormality occurring in live births. In addition, the medical community balanced the cost of offering the testing against their calculation of the cost savings associated with preventing the birth of an infant with Down syndrome.

This past January, ACOG expanded the scope of prenatal testing by recommending for the first time that all pregnant women regardless of age be offered prenatal screening, a process in which a woman’s blood is used to calculate the risk that her fetus has an abnormality.

The December ACOG bulletin will open prenatal testing access wider still. The current bulletin does not explain why the professional organization has now dramatically expanded access to prenatal testing twice within a year. Researchers have maintained that universal access to prenatal testing will allow women to make their own informed decisions regarding their pregnancies and minimize disparities in access to health care.

The changes come at a time when growing numbers of medical malpractice lawsuits are pushing insurance costs for obstetricians and gynecologists to record highs, resulting in a situation that ACOG has called a “medical liability crisis.”

In a statement posted on the group’s website last year, ACOG executive vice president Ralph W. Hale said the rising tide of lawsuits was caused not by a high rate of medical wrongdoing but by unreasonable public expectations. “Ob-gyns are vulnerable because they practice in a high-risk field, and all too often, doctors are held liable for less than perfect outcomes,” he said.

ACOG’s current recommendation seems to thrust the 49,000-member professional organization deeper into the cultural debate over public attitudes toward abortion, particularly about where to draw the line between preventing disability and accepting human diversity.

The National Down Syndrome Congress (NDSC) last January condemned ACOG’s recommendation for universally offered prenatal screening, saying it conveyed “tacit approval for terminating pregnancies where the fetus has Down syndrome.” Studies say that approximately 9 out of 10 pregnancies in the U.S. in which Down syndrome is diagnosed end in abortion.

The NDSC also cited research noting that many doctors are not adequately prepared to deliver a diagnosis of Down syndrome, and often use negative language and out-of-date information.

Down syndrome, which results when a person has three copies of the 21st chromosome instead of the usual pair, is longest known and most common genetic birth defect, as well as the most common cause of intellectual disability. Approximately 250,000-350,000 Americans have Down syndrome, which occurs once in every 733 to 1,000 births, according to the NDSC and the National Down Syndrome Society.

Advocacy groups and parents say gains in health care and education have brought about markedly improved outcomes for these individuals over the past two decades, with many people with Down syndrome now completing high school, holding jobs and living semi-independently. But parents say these gains have not been adequately documented and are poorly understood within the obstetrics community.

In an apparent nod to the NDSC’s criticism, ACOG included in its December practice bulletin for the first time the recommendation that prospective parents who receive a diagnosis of a fetal disorder should be provided with “detailed information, if known, about the natural history of individuals” with the disorder.

ACOG also noted that “it may be very helpful” to refer prospective parents to advocacy groups such as the NDSC or the NDSS.

The bulletin does not, however, offer any recommendations for collecting or distributing information to doctors about the lives of people with Down syndrome or other chromosomal abnormalities, nor for training its 49,000 members in delivering and interpreting prenatal test information. A study published in ACOG’s journal last year found that 45 percent of obstetricians rated their training about prenatal testing as “barely adequate or nonexistent.”

As a result of the new ACOG bulletin, each pregnant woman will now need to decide which is greater: her fear of a chromosomal abnormality, or her fear that invasive testing could harm her fetus. The ACOG bulletin estimates that the risk of miscarriage as a result of the invasive tests is “as low as” one in 300-500, and “may be even lower with experienced individuals or centers.” Other estimates say that approximately one in every 200 women who undergoes invasive testing will miscarry her pregnancy.

The risk of a fetus with a chromosomal abnormality varies with the mother’s age. According to ACOG data, the lowest recorded risk goes to 19-year-olds, with a risk of 1 in 555, and the highest goes to a 49-year-old, with a risk of 1 in 6.

The financial impact of the new ACOG bulletin is not known, but could extend above the billion-dollar mark. Amniocentesis and chorionic villus sampling (CVS), the invasive tests, are both more expensive and more accurate than the maternal blood test screens. The consumer cost of each amniocentesis is more than $1,000. Chorionic villus sampling costs between $600 and $1200. More invasive tests would also call for an increase in costs for training, facilities and equipment.

Amniocentesis and CVS each involve removing and examining material from inside the uterus during pregnancy with a long needle or plastic tube to check for chromosomal differences.

The maternal blood-test screens do not deliver definitive results but only report the odds that a particular fetus may have an abnormality. They also carry a significant risk of both false positives and false negatives.

In a tacit acknowledgment of the ongoing abortion debate, the bulletin notes that “Prenatal diagnosis is not performed solely for assistance in the decision of pregnancy termination. It can provide useful information for the physician and the patient.”

The practice bulletin listed the recommendation for offering invasive diagnostic testing to all pregnant women as a “Level C” recommendation, one that is “based primarily on consensus and expert opinion.” This is the lowest rank used in justifying ACOG recommendations.

Higher rankings that may be used for ACOG recommendations are “Level A” (”based on good and consistent scientific evidence”) and “Level B” (”based on limited or inconsistent scientific evidence.”)

Thursday, December 13, 2007

Diet & Nutrition Study

DSRF is doing a new study:

Nutritional Interventions in Children wtih Down's syndrome (NICDS study)
"Can nutritional intervention prevent or reduce the risks of associated diseases and illnesses in Down's syndrome?"

For more information on the study, here's a link ~
http://www.dsrf.co.uk/2007ResearchStudy/dietandnutrition.html

"
The aim of this study is to see if nutritional interventions can help to prevent or reduce the risks that children with Down's Syndrome are exposed to in terms of illnesses such as type 2 diabetes, vascular disease, obesity, leukaemia and early onset dementia. Much is known about the ways in which nutrition and lifestyle can be modified to prevent, or at least reduce the risk of these disorders."

Monday, December 3, 2007

Website for Book - Down Syndrome: What You CAN Do

As some may know, my mother and I are in the process of writing a book about Down syndrome. The title is going to be "Down Syndrome: What You CAN Do." I put a website up with information about the book. The link is:

Like Any Other Boy

I wrote this and submitted it to the Band of Angels site for the brothers & sisters column on the site by Harper Kidder.

~~~~~~~

Like Any Other Boy

I’m the oldest of 11 children. One of my 4 brothers is 2 ½ years old. He also happens to have a twin sister, who is 5 minutes younger than him.

My brother is like any other little boy. He likes to play with cars. He likes to run and play outside. When he hears that one of the kids is going outside, he always asks to have his shoes put on and to go outside with them. He chases his twin sister around. He really enjoys playing ball. When all the other kids play pass the ball, he is right there with them passing the ball. He even likes to play with baby dolls with his twin sister!

One of his favorite things to do is dance! He dances all the time and is so cute. He has some of the cutest little jigs and rhythm. Often times the whole family will be watching him dance because it’s such a blast watching him. One of the best times when it comes to dancing was at this past Thanksgiving at our friend’s house. All of us (including our friends who were there) were in a big circle and each person was taking their turn doing a dance in the middle while everyone followed them. It finally came to where everyone had done it, so we asked my bother to come in the middle and dance. He did it perfectly!

I guess I should mention now that my brother has Down syndrome. When my brother was born his diagnosis was news to us. But, contrary to the “he can’t” and “he won’t” statements that we were told back on that February day 2 ½ years ago, my brother has exceeded and shown that those statements were wrong. He is just a part of our family; one of the kids. He can do a lot.

One thing about him is that he is so loving, so happy almost all the time and so much fun. He puts a smile on our faces! We are thankful that God has shown great mercy on him and us and made him excel way beyond what we were told.

- Qadoshyah

19 yr. old sister to boy(DS)/girl twins - February. 05

Related Posts with Thumbnails